We are live on ! Find out more
PVCT

PROVECTUS BIOPHARMACEUTICALS, INC. (DE)
PVCT

Delisted

PVCT was delisted on the 13th of October, 2016.

Back to rankings

7 hedge funds and large institutions have $36.8K invested in PROVECTUS BIOPHARMACEUTICALS, INC. (DE) in 2023 Q1 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, 0 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

52% more capital invested

Capital invested by funds: $24.2K → $36.8K (+$12.6K)

0% more funds holding

Funds holding: 7 → 7 (0)

Holders
7
Holders Change
–
Holders Change %
0%
% of All Funds
0.11%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
HFBOT
1
Home Federal Bank of Tennessee
Tennessee
$16.5K – – –
LDB
2
Lee, Danner & Bass
Tennessee
$8K – – –
AW
3
Atlas Wealth
Ohio
$4.39K – – –
LIA
4
LBMC Investment Advisors
Tennessee
$3.63K – – –
ACM
5
Academy Capital Management
Texas
$3K – – –
AA
6
Ancora Advisors
Ohio
$1.26K – – –

PVCT Hedge Fund Activity: Q1 2023 in Review

7 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in PROVECTUS BIOPHARMACEUTICALS, INC. (DE) (PVCT) for Q1 2023, worth a combined $36.8K — up 52% from $24.2K a quarter earlier.

Fund positioning in PVCT was balanced in Q1 2023: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 0 trimmed.

  • 7 institutional investors held PROVECTUS BIOPHARMACEUTICALS, INC. (DE) (PVCT) as of Q1 2023, unchanged from Q4 2022.
  • Funds reported $36.8K of PROVECTUS BIOPHARMACEUTICALS, INC. (DE) stock for Q1 2023, up 52% quarter-over-quarter.
  • 0 funds opened new PROVECTUS BIOPHARMACEUTICALS, INC. (DE) positions in Q1 2023 and 0 closed out.

Based on aggregated 13F filings for Q1 2023.